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Abstract
 
Although numerous chemokines act on monocytes, none of them is specific for these cells.
Here, we show that breast and kidney–expressed chemokine (BRAK) is a highly selective
monocyte chemoattractant. Migration efficacy and 
 
Bordetella pertussis
 
 toxin–sensitive Ca
 
2
 
 
 
 mo-
bilization responses to BRAK were strongly enhanced after treatment of monocytes with the
 
cyclic AMP–elevating agents prostaglandin E
 
2
 
 and forskolin. BRAK is the first monocyte-
selective chemokine, as other types of blood leukocytes or monocyte-derived dendritic cells
and macrophages did not respond. Expression in normal skin keratinocytes and dermal fibro-
blasts as well as lamina propria cells in normal intestinal tissues suggests a homeostatic rather
than an inflammatory function for this chemokine. In addition, macrophages were frequently
found to colocalize with BRAK-producing fibroblasts. We propose that BRAK is involved in
the generation of tissue macrophages by recruiting extravasated precursors to fibroblasts, which
are known to secrete essential cytokines for macrophage development.
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2 
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Introduction
 
Homing of leukocytes to sites of hematopoiesis, antigen
priming, immune surveillance, and inflammation largely
depends on the presence of chemokines (1–3). Approxi-
mately 50 human chemokines are currently known, and
this large number reflects the highly complex traffic pattern
of precursor and mature blood leukocytes. In broad terms,
the chemokines are divided into two functional subfami-
lies, the inflammatory and the homeostatic chemokines, al-
though several chemokines share both features. Recent
progress draws attention to several chemokines with a cen-
tral role in the basal lymphocyte traffic in extra-lymphoid
tissues, such as skin and gastrointestinal tract (for reviews,
see references 1–3). Cutaneous T cell–attracting chemo-
kine (CTACK; CCL27) and mucosae-associated epithelial
chemokine (MEC; CCL28), two recent CC chemokines
with selectivity for the receptor CCR10, are expressed in
various epithelial tissues. Thymus and activation-regulated
chemokine (TARC) is present in (notably inflamed) skin
tissue and attracts cutaneous lymphocyte antigen (CLA)
 
  
 
T
cells more efficiently than CLA
 
 
 
 T cells, correlating with
expression of CCR4, the receptor for TARC and mono-
cyte-derived chemokine (MDC; CCL22), on CLA
 
 
 
 pe-
ripheral blood memory T cells. Finally, thymus-expressed
chemokine (TECK; CCL25), a chemokine with high ex-
pression in intestinal epithelia, selectively interacts with
CCR9 expressed on gut-homing T cells. Of note, TARC,
MDC, and TECK are also present in lymphoid tissues and
attract T cell precursors, indicating that they are not
uniquely involved in the control of mature lymphocyte
traffic (1–3). Despite remarkable progress in the under-
standing of lymphocyte migration in epithelial tissues, there
is currently no information about chemokines, which con-
trol the traffic of monocytes at these locations.
 
Breast and kidney–expressed chemokine (BRAK; CXCL14)
 
is a recent CXC chemokine with unknown function and
receptor selectivity (4–6). The mature sequences of
BRAK and its murine ortholog SK1 contain 77 amino ac-
 
ids and are unique with regard to the short NH
 
2
 
-terminal
end of only two amino acids (Ser-Lys), preceding the first
of four chemokine-typical Cys residues. There is some
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controversy with respect to the tissues that express this
chemokine. BRAK transcripts are highest in human kid-
ney, small intestine, and liver tissues, whereas SK1 tran-
scripts predominate in mouse ovary, brain, and lung tissues
but not in murine kidney, intestine, and liver tissues (4–6).
Here we demonstrate that BRAK is a highly selective che-
mokine for blood monocytes. Constitutive expression in
normal skin and intestinal tissues suggests a homeostatic
rather than an inflammatory role for BRAK, which is pos-
sibly related to macrophage development.
 
Materials and Methods
 
Reagents and Antibodies.
 
Synthetic chemokines were prepared
as described (7). GM-CSF and IL-4 were purchased from Pepro-
Tech, prostaglandin E2 from Fluka, and forskolin and LPS from
Sigma-Aldrich. MicroBead-labeled mouse anti–human CD4,
CD8, CD14, CD20, and CD56 antibodies were from Miltenyi
Biotec, and anti-CD3 and S-100 rabbit IgG, and anti-CD20
(L26) and anti-CD68 (PG-M1) mouse monoclonal antibodies
were from Dako. Synthetic oligonucleotide primers were from
MWG Inc.
 
Blood Cell Isolation, Cell Culture, and Chemokine Responses.
 
Isolation of human PBLs, monocytes, and neutrophils, and cul-
turing of T cells are described (8, 9). Macrophages were gener-
ated by culturing of CD14
 
 
 
 monocytes in normal or Teflon foil–
coated culture dishes for 5–7 d in macrophage serum–free
medium (Life Technologies) with or without 10 ng/ml GM-
CSF. The generation of monocyte-derived dendritic cells (DCs)
is described elsewhere (10, 11). Stimulation of monocytes with
either 1 
 
 
 
M PGE
 
2
 
 or 20 
 
 
 
M forskolin was performed in Teflon
foil–coated culture dishes. Chemotaxis and Ca
 
2
 
 
 
 mobilization as-
says are described elsewhere (12).
 
Northern Blot and PCR Analysis.
 
RNA was extracted from
blood leukocytes, tissue culture cell lines, primary cultures of ke-
ratinocytes, and dermal fibroblasts or whole tissue sections either
by the RNAzole B method (Tel-Test Inc.) or by using FP120
FastPrep RNA extraction machine (Savant Instruments Inc.) ac-
cording to the suppliers instruction. Human epidermis and ke-
ratinocytes were prepared from skin tissue (mamma reduction)
as described (13). Epidermal single cell suspensions were ob-
tained by trypsin digestion. Northern blot was performed with a
 
32
 
P-labeled 314-bp BRAK DNA probe containing the entire
coding region (sequence data are available from GenBank/
EMBL/DDBJ under accession no. AF073957). The oligonucle-
otide primers used in reverse transcription (RT)-PCR included
those for glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
sense ACATCAAGAAGGTGGTGAAGCAGG, and antisense
CTCTTCCTCTTGTGCTCTTGCTGG; 282-bp fragment,
GenBank/EMBL/DDBJ accession no. M33197); 
 
 
 
-actin (sense
CAGGGCGTGATGGTGGGCATG, and antisense GGCGAC-
GTAGCACAGCTTCTCC; 540-bp fragment, GenBank/EMBL/
DDBJ accession no. X00351); BRAK (sense TCCGGTCAG-
CATGAGGCTCC, and antisense CACCCTATTCTTCGTA-
GACC; 314-bp fragment, GenBank/EMBL/DDBJ accession no.
AF073957); CTACK (sense GAGTCTAGGCTGAGCAACAT-
GAAGG, and antisense GCTTCAGCCCATTTTCCTTAG-
CATCC; 360-bp fragment, GenBank/EMBL/DDBJ accession
no. AJ243542); and TECK (sense ATGAACCTGTGGC-
TCCTGG, and antisense GGCTCACAGTCCTGAATT-
AGC; 456-bp fragment, GenBank/EMBL/DDBJ accession no.
U86358).
 
Immunohistochemistry and In Situ Hybridization.
 
Paraffin tissue
sections were immunostained with anti-CD68, anti–S-100 (after
proteinase digestion), anti-CD3, anti-CD20 (after heat retrieval),
and isotype control antibodies by the ABC method (9). For in
situ hybridization, 
 
35
 
S- or digoxigenin-labeled sense and antisense
mRNA corresponding to position 
 
 
 
10 to 304 of BRAK cDNA
(GenBank/EMBL/DDBJ accession no. AF073957) was gener-
ated and used as described (9). Combined immunostaining and in
situ hybridization: initial antibody binding, in buffers treated with
diethyl pyrocarbonate containing 5 mg/ml heparin sodium salt
(Sigma-Aldrich) and 5 mg/ml nuclease-free bovine serum albu-
min (Calbiochem), was developed with FastRed (Sigma-Aldrich).
After paraformaldehyde fixation and acetylation, hybridization
with digoxigenin-RNA probes was performed and detected by
NBT/BCIP (Roche).
 
Results
 
BRAK Is Selective for Activated Peripheral Blood Mono-
cytes.
 
Freshly isolated peripheral blood leukocytes, in-
cluding isolated neutrophils, T, B, and NK cells, did not
migrate in response to BRAK, as assessed in the modified
Boyden chamber chemotaxis assay (not shown). In addi-
tion, no activity was found with numerous T cell lines de-
rived from peripheral blood or tonsils, irrespective of their
state of activation (short-term activated, proliferating, or
resting) or stimulatory conditions (PHA, anti-CD3/CD28
antibodies or superantigen-loaded DCs). However, migra-
tion responses were frequently observed with freshly iso-
lated monocytes (37 
 
 
 
 21 cells/5 high power fields [HPF];
 
n
 
 
 
 
 
 8) with background migration (in the absence of
chemokines) not exceeding 8 cells/5 HPF (Fig. 1 a), sug-
gesting that a subpopulation within the monocyte prepara-
tions was attracted by BRAK. Selectivity of BRAK for
CD14
 
 
 
 monocytes was confirmed in Transwell migration
assays with unfractionated peripheral blood mononuclear
cells (Fig. 1 b). The 15-fold enrichment in CD14
 
 
 
 mono-
cytes is an underestimate due to BRAK-independent
(background) migration of CD14-negative cells. Mono-
cyte-derived (immature or mature) DCs and macrophages
did not respond. However, short-term treatment of mono-
cytes with a combination of GM-CSF, IL-4, and PGE
 
2
 
consistently produced BRAK migration responses, and this
observation was further examined.
GM-CSF and IL-4 alone or in combination had no ef-
fect whereas stimulation of peripheral blood monocytes
with PGE
 
2
 
 resulted in robust responsiveness to BRAK
within 1–3 d of culture, and this effect was lost during pro-
longed culture (Fig. 1 c). BRAK responses peaked at day 1
or 2 of PGE
 
2
 
 treatment with 84 to 234 migrated cells/5
HPF (165 
 
  
 
61 cells/5 HPF; 
 
n
 
 
 
 
 
 8), whereas background
migration in the absence of BRAK was negligible (
 
 
 
8 mi-
grated cells/5 HPF). By comparison, monocytes cultured
for 2 d in the absence of PGE
 
2
 
 responded weakly to BRAK
(37 
 
  
 
38 cells/5 HPF; 
 
n 
 
 
 
 7). Of note, marked chemotaxis
was only seen at high BRAK concentrations (
 
 
 
100 nM),
resembling homeostatic chemokines, which induce chemo-
taxis at high concentrations as opposed to inflammatory
chemokines (1–3). In clear contrast, strong migration re- 
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sponses of freshly isolated monocytes to monocyte
chemoattractant protein (MCP-1; CCL2), regulated on
activation, normal T cell expressed and secreted
(RANTES; CCL5), and stromal cell–derived factor
(SDF)-1 (CXCL12) were not maintained during monocyte
culture, and lowest migration was consistently seen after 1 d
of PGE
 
2
 
 stimulation (Fig. 1 c, and data not shown). Induc-
tion of BRAK responses by PGE
 
2
 
 was selective for mono-
cytes, as the same treatment of peripheral blood T and B cells
did not result in responsiveness to BRAK (not shown).
PGE
 
2
 
 interacts with numerous heptahelical receptors, which
activate adenylate cyclase via coupling to heterotrimeric G
proteins of the G
 
s
 
 subclass. To determine the requirement
for cAMP in induction of BRAK responsiveness, mono-
cytes were examined after culturing in the presence of the
adenylate cyclase activator forskolin. Indeed, forskolin was
equally effective as PGE
 
2
 
 in inducing monocyte respon-
siveness to BRAK (Fig. 1 d). Peak migration responses
(134 
 
  
 
39 cells/5 HPF; 
 
n 
 
 
 
 4) were obtained at day 2 or 3
of culture, which then declined to base levels by day 6.
BRAK responses of cultured but untreated monocytes
were moderate (53 
 
  
 
33 cells/5 HPF; 
 
n 
 
 
 
 4). Migration
responses to MCP-1 (or RANTES and SDF-1, not shown)
were consistently reduced, which fully agrees with the re-
ported PGE
 
2
 
 effect (14–16). Together, the stimulatory ef-
fect of forskolin closely matches our findings with PGE
 
2
 
and demonstrates that an adenylate cyclase–dependent
mechanism was involved in induction of monocyte re-
sponsiveness to BRAK.
 
BRAK Signals through Bordetella pertussis toxin–sensitive
Receptors.
 
In addition to chemotaxis, BRAK induced
rapid elevations in the concentration of intracellular free
Ca
 
2
 
 
 
 in PGE
 
2
 
-treated monocytes, which is a typical and
rapid response to chemokine receptor signaling (Fig. 2). As
Figure  1. BRAK is a selective chemoattractant for
PGE2- and forskolin-treated monocytes. (a) Peripheral
blood monocytes respond weakly to BRAK. Freshly iso-
lated peripheral blood monocytes were examined for
chemotaxis responses to BRAK (circles), and MCP-1
(squares) at indicated concentrations. (b) In Transwell
chemotaxis assays with freshly isolated peripheral blood
mononuclear cells (input cells), BRAK recruited predomi-
nantly CD14  monocytes, as assessed by flow cytometric
analysis of migrated cells. (c) PGE2 treatment of monocytes
induces strong migration responses to BRAK. Peripheral
blood monocytes were cultured in the presence (filled
symbols) or absence (open circles) of PGE2 for indicated
number of days and examined for chemotaxis responses to
1  M BRAK (circles) or 10 nM MCP-1 (squares). (d)
Forskolin can substitute for PGE2 in induction of mono-
cyte responsiveness to BRAK. Peripheral blood monocytes
were cultured in the presence (filled symbols) or absence
(open circles) of forskolin, and cells were examined for
chemotaxis responses to 1  M BRAK (circles) or 10 nM
MCP-1 (squares) at indicated days of culture. Single data
point are the mean of triplicate values, each representing
the number of migrated cells per 5 HPF.
Figure 2. BRAK-mediated elevation of intracellular free
Ca2  concentrations in PGE2-treated monocytes. Freshly
isolated monocytes or monocytes cultured for 2 d in the
presence of PGE2 were examined by real-time Fura-2
fluorescence recordings for Ca2  mobilization responses to
0.01–1  M BRAK and 0.1  M MCP-1. Preincubation of
PGE2-treated monocytes with PT abolished Ca2  mobili-
zation responses to 0.1  M BRAK and MCP-1. Arrow-
heads denote time of chemokine additions. 
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expected from the chemotaxis data, BRAK-mediated Ca
 
2
 
 
 
signals in freshly isolated monocytes were weak and only
detected at 1 
 
 
 
M concentrations. By contrast, both un-
treated and PGE
 
2
 
-treated monocytes showed strong Ca
 
2
 
 
 
-
mobilization responses to MCP-1. Onset, rate, and maxi-
mal height of BRAK-induced Ca
 
2
 
 
 
 signals resemble those
induced by MCP-1, whereas restoration of base level intra-
cellular Ca
 
2
 
 
 
 concentrations occurred much slower, sug-
gesting a delay in BRAK receptor desensitization. Chemo-
kine receptors couple to heterotrimeric G proteins of the
 
B. pertussis
 
 toxin (PT)-sensitive G
 
 
 
i
 
 subclass (1), and PT
sensitivity of the BRAK response demonstrates that the
BRAK receptor couples to the same type of signaling ele-
 
ments. Ca
 
2
 
 
 
-mobilization screening of transfected cells ex-
pressing known or putative chemokine receptors failed to
identify the BRAK receptor and, together with the unique
selectivity of BRAK for monocytes, supports the notion
that BRAK interacts with a new as yet unidentified
chemokine receptor.
 
BRAK Expression in Epithelial Tissues.
 
In an RNA dot-
blot analysis of 50 human tissues, highest BRAK transcript
levels were found in epithelial tissues, foremost in small in-
testine and kidney, followed by stomach, colon, appendix,
and trachea (not shown). Skin RNA was not represented
on this blot (see below). Evidently, BRAK expression
marks epithelial tissues with prevalent exposure to anti-
Figure 3. BRAK expression in skin and gut mucosal tissues. In situ hybridization of paraffin-embedded sections using 35S-labeled (a, c–f) or digoxige-
nin-labeled (b) antisense BRAK RNA probes. (a) BRAK expression (black) in normal skin; arrowheads point at some BRAK-positive cells in the dermis.
Control staining with a sense BRAK RNA probe is shown in the inset. (b) Double staining of dermal cells in normal skin with an antisense BRAK RNA
probe (black) and anti-CD68 antibodies (red). (c) BRAK expression in skin with atopic dermatitis (arrowhead depicts lymphocytic infiltrate), and (d)
basal cell carcinoma (asterisk denotes tumor mass); control sense probe staining in the inset. (e) BRAK transcripts in the small intestine of a healthy indi-
vidual; control sense probe staining in the inset. (f) BRAK expression in Crohn’s disease (asterisk denotes ulcerated tissue). Original magnifications: (f)
 40; (a, d, and e)  100; (c)  200; (b)  600. 
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gens, and these sites were further studied by in situ hybrid-
ization analysis. Strong signals with antisense but not sense
 
35
 
S-labeled BRAK RNA probes were detected in the epi-
dermis of normal skin (Fig. 3 a). Of note, BRAK message
was highest in basal keratinocytes of the epidermis and in
scattered cells within the underlying dermis. Within the
epidermis BRAK signals were most prominent in the basal
layer of keratinocytes and were fading out toward the
outer layers, indicating that BRAK production diminished
with keratinocyte differentiation. In the dermis, BRAK-
positive cells were frequently found side-by-side with
(CD68
 
 
 
) macrophages, as evidenced by in situ hybridiza-
tion with a digoxigenin-labeled BRAK RNA probe in
combination with immunohistochemistry (Fig. 3 b). Of
232 
 
  
 
29 hematoxylin-positive cells/mm
 
2
 
 (total area with-
out perivascular space: 6.3 mm
 
2
 
), 99 
 
  
 
16 cells stained pos-
itive for BRAK and 77 
 
  
 
9 cells stained positive for mac-
rophages, and 20 
 
  
 
3% of these macrophages were found
to be “paired” with BRAK-positive cells. This phenome-
non was not observed with other infiltrated cells, including
T cells (CD3), B cells (CD20), and Langerhans cells (S-
100) or endothelial cells (CD31) (not shown). Further, T
cells, B cells, and DCs represented minor cell populations
(each 
 
 4 cells/mm2), suggesting fibroblasts as the source of
dermal BRAK.
Of interest, in atopic dermatitis (examined in three indi-
viduals; Fig. 3 c) and psoriasis (examined in three individu-
als; not shown) the uniform and strong expression of epi-
dermal BRAK transcripts was interrupted at sites where
basal keratinocytes were in contact with inflammatory cells,
whereas dermal BRAK expression remained unchanged.
Possibly, interaction of keratinocytes with T cells, which
predominated the inflammatory infiltrates, caused this
marked inhibition. Finally, BRAK expression was promi-
nent in skin sections of two patients with basal cell carci-
noma, with strong hybridization signals at the border but
fading out toward the center of the tumors (Fig. 3 d),
whereas tumor tissue of a patient with squamous cell carci-
noma was negative (not shown). Again, dermal BRAK ex-
pression was normal in both types of skin tumors.
In contrast to skin, epithelial cells in the small intestine
and colon (not shown) did not show any sign of BRAK
expression whereas strong hybridization signals were de-
tected in cells within the lamina propria (Fig. 3 e). Here,
BRAK-positive cells were more concentrated in the apical
as opposed to basolateral parts and were absent in the soft
tissue distant from the mucosal epithelia. Of note, CD68 
macrophages were also located along the uppermost aspect
of the lamina propria near the tips of the villi (not shown).
The ulcerated tissue of a patient with Crohn’s disease, in-
cluding large numbers of mostly B cells and some T cells, as
well as adjacent lymphoid follicles did not show signs of
BRAK expression (Fig. 3 f). As in normal small intestine,
BRAK-positive cells were readily detected in unaffected
lamina propria tissue.
BRAK expression in epithelial tissues was further exam-
ined by Northern blot and RT-PCR analysis. A single hy-
bridization signal corresponding to an RNA species of 1.8
kb was detected in total RNA extracted from human skin
and small intestine tissue (Fig. 4 a). In addition, intact
epidermal tissue and trypsin-extracted epidermal cells
contained detectable levels of BRAK transcripts whereas
human epidermis– and gut epithelia–derived cell lines, in-
cluding keratinocytes (HaCat), melanoma cells (Hs294T),
epidermoid (A431), colon (Caco-2), and cervix (Hela) car-
cinoma cells, fibrosarcoma cells (HT1080), lung carcinoma
cells (A549), embryonic kidney cells (E293), and dermal
microvascular endothelial cells (HMEC-1), were negative.
Strong BRAK hybridization signals with RNA from epi-
dermis and keratinocyte-rich cell extracts (epidermal ex-
tract) as opposed to epithelia-derived cell lines from gut
mucosal tissue is in agreement with the results from in situ
analysis (Fig. 3).
Confirming the Northern blot results, BRAK RT-PCR
products are readily observed in RNA from skin, epidermis
as well as gastrointestinal tissues (appendix, jejunum, and il-
eum), as well as primary cultures of epidermal keratinocytes
and dermal fibroblasts (Fig. 4 b). Although not detected by
Northern blot, HaCat, in submerged cultures resembling
undifferentiated keratinocytes, were positive in RT-PCR
whereas melanoma-derived HS294T, colon epithelium–
derived Caco-2, or PBLs were negative. BRAK cDNA
from monocytes was only seen after extended amplification
(not shown). PCR amplification of CTACK and TECK
cDNA served as a control and confirmed the inverse rela-
tionship of their respective RNA expression in skin and gut
tissue (1–3).
Figure 4. BRAK transcript expression in epithelial cells and fibroblasts.
(a) Northern blot analysis of skin and gut tissues, extracted cells, or related
cell lines with a 32P-labeled BRAK DNA probe. Bottom panel, ethidium
bromide–stained RNA as agarose gel loading control. (b) RT-PCR anal-
ysis of BRAK transcripts. In addition to RNA samples as outlined above,
RNA extracted from freshly isolated keratinocytes, primary dermal fibro-
blast cultures, appendix, and ileum tissues were examined. PCR amplifi-
cation of GAPDH and  -actin (not shown) cDNA sequences was per-
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Discussion
BRAK is not a chemoattractant for peripheral blood T,
B, and NK cells or neutrophils. By contrast, BRAK-
responsive cells were found to be present among blood
monocytes. Furthermore, culturing of monocytes (but not
T or B cells) in the presence of PGE2 resulted in strong mi-
gration and Ca2  mobilization responses to BRAK, with
peak activities seen between day 1 and 2, followed by a de-
cline to base level activities similar to those observed with
freshly isolated blood monocytes. Of note, BRAK is a
highly efficient chemokine for PGE2-treated monocytes (as
evidenced by migration indices of  40), exceeding by far
the effect seen with a murine histidine-tagged BRAK pro-
tein on two human cell lines (6). Monocyte-derived imma-
ture/mature DCs and macrophages did not respond to
BRAK. We conclude that BRAK is a highly selective
chemokine for circulating and PGE2-treated monocytes.
PGE2, like many other prostanoids, is a powerful media-
tor of inflammation, and its production under inflamma-
tory settings as well as its modulatory functions in pyrexia,
algesia, and edema are well documented (17). With regard
to leukocytes, PGE2 is both a pro- and antiinflammatory
mediator. Relevant to this study are several reports show-
ing that PGE2 inhibits (rather than promotes) migration
and effector functions in neutrophils, monocytes, and lym-
phocytes (14, 16, 18, 19). Some of these inhibitory effects
were shown to be mediated by cAMP, suggesting the in-
volvement of Gs-coupled PGE2 receptors (14, 16, 20, 21).
This is in marked contrast to the PGE2-induced monocyte
responsiveness to BRAK, which also depended on elevated
intracellular cAMP levels, as shown with forskolin. As nu-
merous stimuli induce cellular responses via adenylate cy-
clase activation, PGE2 may not be the sole physiological
agent rendering monocytes responsive to BRAK. An at-
tractive concept for future BRAK studies will center on
leukocyte adhesion and transendothelial migration, which
involves multiple, in part cAMP-dependent signaling
events leading to leukocyte gene expression and differenti-
ation (22, 23). Collectively, the positive effect of PGE2 and
forskolin on monocyte responsiveness to BRAK clearly sets
this chemokine apart from other known chemoattractants.
A crucial element for defining the physiological role of
BRAK is a detailed understanding of the cellular sources
and circumstances (normal versus inflammatory conditions)
under which this chemokine is produced. We find promi-
nent BRAK in situ hybridization signals in the basal layer
of epidermal keratinocytes and dermal cells of skin tissue as
well as in lamina propria cells (but not epithelial cells) of
colon and small intestine. Expression in basal cell carci-
noma, a neoplastic disorder of basal keratinocytes, as op-
posed to squamous cell carcinoma, fully agrees with un-
differentiated as opposed to terminally differentiating
suprabasal keratinocytes as the primary source of epidermal
BRAK. Presence of BRAK transcripts in submerged pri-
mary cultures of keratinocytes and related cell lines was
confirmed by Northern blot and RT-PCR analysis. Fur-
ther, we propose that fibroblasts are the source of BRAK,
as frequency, tissue distribution, and lack of costaining with
a digoxigenin-labeled BRAK RNA probe exclude other
candidate cell types in the dermis (T and B cells, macro-
phages, Langerhans cells, endothelial cells). In support, pri-
mary dermal fibroblast cultures contained similar levels of
BRAK transcripts as primary keratinocyte cultures. Impor-
tantly, BRAK-producing cells in the dermis and lamina
propria were frequently found in company with macro-
phages, suggesting that this chemokine marks sites of mac-
rophage differentiation.
Constitutive expression in normal skin and gut tissues
qualifies BRAK as a novel member of homeostatic
chemokines. However, the powerful effect of PGE2 in in-
duction of monocyte responses to BRAK does not exclude
a role for this chemokine in inflammation. We propose that
BRAK is involved in the homeostasis of monocyte-derived
tissue macrophages, as IL-6 from dermal fibroblasts was re-
cently shown to determine macrophage differentiation (24,
25). During microbial infections, inflammatory chemo-
kines regulate the recruitment of monocytes to inflamma-
tory sites where PGE2 induces the transition from refrac-
tory to BRAK-responding cells. This change in migratory
pattern allows macrophage precursors to colocalize with
BRAK-producing fibroblasts for further development into
macrophages, thus explaining the frequent colocalization of
BRAK-producing fibroblasts with CD68  cells in the der-
mis. Under normal conditions (in the absence of inflamma-
tory PGE2), monocytes exit blood circulation constitutively
by an unknown but possibly an inflammatory chemokine-
independent mechanism. As adhesion and transendothelial
migration results in functional and phenotypic changes in
leukocytes (22, 23), it is tempting to speculate that extrava-
sation enhances monocyte responsiveness to BRAK. Alter-
natively, the fraction of BRAK-responsive monocytes al-
ready present in blood may enter skin tissue to become a
target for fibroblast-derived BRAK, thus allowing their in-
flammation-independent development into macrophages.
In summary, we propose that BRAK regulates the traffic of
macrophage precursors at niches in skin and mucosal tissues
that support their further development.
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